Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy

<p>Abstract</p> <p>Background</p> <p>MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies have shown altered expression levels of several microRNAs in renal cell carcinoma.</p> <p>Methods</p> <p>We examined the expression levels of selected microRNAs in 38 samples of conventional renal cell carcinoma (RCC) and 10 samples of non-tumoral renal parenchyma using TaqMan real-time PCR method.</p> <p>Results</p> <p>The expression levels of miRNA-155 (p < 0.0001), miRNA-210 (p < 0.0001), miRNA-106a (p < 0.0001) and miRNA-106b (p < 0.0001) were significantly over-expressed in tumor tissue, whereas the expression of miRNA-141 (p < 0.0001) and miRNA-200c (p < 0.0001) were significantly decreased in RCC samples. There were no significant differences between expression levels of miRNA-182 and miRNA-200b in tumor samples and renal parenchyma. Our data suggest that expression levels of miRNA-106b are significantly lower in tumors of patients who developed metastasis (p = 0.030) and miR-106b is a potential predictive marker of early metastasis after nephrectomy in RCC patients (long-rank p = 0.032).</p> <p>Conclusions</p> <p>We have confirmed previous observations obtained by miRNA microarray analysis using standardized real-time PCR method. For the first time, we have identified a prognostic significance of miRNA-106b, which, after validation on a larger group of patients, maybe useful as a promising biomarker in patients with RCC.</p

A rare adverse reaction of sorafenib

Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its receptor. The European Medicines Agency (EAMA) and Food and Drug Administration (FDA) approved the use of sorafenib in late-stage hepatic cellular cancer (HCC) on October 30, 2007, and November 19, 2007, respectively. It is the only drug approved for use in the systematic treatment of primary HCC, and it offers renewed hope for middle- and late-stage liver cancer patients. Conventional use of sorafenib is 400 mg orally, twice daily, until tumor progression or patient death. The following is a report of a serious episode of skin rash in a liver cancer patient at our hospital subsequent to treatment with sorafenib

Krajinně-ekologické‚ vodohospodářské‚ ekonomické a legislativní hodnocení záměru výstavby kanálu Dunaj - Odra - Labe:Vliv potenciální výstavby kanálu Dunaj - Odra - Labe na biodiverzitu lužních lesů

Orientační ekologická charakteristika ekosystémů lužních lesů v ČR, které by byly dotčeny potenciální výstavbou vodního kanálu DOL. Stručné shrnutí dosavadních poznatků o vlhkostním režimu půd lužních lesů a vlivu vodohospodářských úprav na ekosystémy lužních lesů

Supplementary Material for: Long-term efficacy and safety of enzalutamide monotherapy in elderly patients with metastatic castration-resistant prostate cancer - case report

Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy